Every 10-Q that Puma Biotechnology Inc (PBYI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PBYI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PBYI filings page.
Puma Biotechnology, Inc. reported Q2 2026 total revenue of $56,502 (thousands), up from $52,436 (thousands) a year earlier, driven by product revenue of $53,560 (thousands) and royalty revenue of $2,942 (thousands). Q2 net income was $8,189 (thousands), compared with $5,855 (thousands) in Q2 2025, with diluted EPS of $0.16.
For the first six months of 2026, revenue was $101,316 (thousands) and net income was $4,436 (thousands). As of June 30, 2026, total assets were $192,736 (thousands), including cash, cash equivalents and marketable securities totaling approximately $93.9 million, and stockholders’ equity was $138,544 (thousands). Long-term debt was reduced to $0 after repayment of the Athyrium Notes, while the company continues to commercialize NERLYNX® and develop alisertib. Management believes existing liquidity and expected cash flows are sufficient to meet operating needs for at least one year after this Form 10-Q is filed, while noting potential uncertainty from new U.S. pharmaceutical import tariffs.
Puma Biotechnology reported a small net loss for the first quarter of 2026 as higher research spending offset steady sales of its cancer drug NERLYNX. Total revenue was $44.8 million, slightly below $46.0 million a year earlier, as product and royalty revenue both declined modestly.
Operating costs rose to $48.6 million from $42.0 million, driven mainly by research and development expenses increasing to $19.8 million from $13.9 million. The company posted a net loss of $3.8 million, or $0.07 per share, compared with net income of $3.0 million, or $0.06 per share, in the prior-year quarter.
Despite the loss, Puma generated $15.4 million of cash from operating activities and ended the quarter with $101.5 million in cash, cash equivalents and marketable securities. Long-term debt under the Athyrium Notes was largely repaid, with $11.3 million classified as current, and stockholders’ equity stood at $128.4 million. Management believes existing cash and expected receipts from product sales and sub-license payments can fund operations for at least one year after this report.
Puma Biotechnology (PBYI) reported Q3 2025 results. Total revenue was $54.5 million, with product revenue of $51.9 million and royalty revenue of $2.6 million. Net income was $8.8 million, or $0.17 per diluted share. Operating costs and expenses were $44.9 million, yielding income from operations of $9.6 million.
For the nine months ended September 30, 2025, revenue was $152.9 million and net income was $17.7 million. Operating cash flow totaled $27.4 million. Cash, cash equivalents and marketable securities were $94.4 million as of September 30, 2025. Long-term debt, net, was $0 at quarter-end, and the current portion of long-term debt was $33.7 million.
Stockholders’ equity rose to $115.3 million from $92.1 million at year-end. Shares outstanding were 50,391,107 as of November 3, 2025. The company continues to commercialize NERLYNX and to develop alisertib under its license from Takeda.